DB18277InvestigationalGene Therapies
OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).
- Also known as
- AAV-hNR2E3
- Code names
- OCU-400
Resolves to
Compound
What you can answer from here — as of September 25, 2025
Which companies are running trials of OCU400, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account